According to current market reports, drug expenses will amount to 1.5 trillion US dollars globally in 2021. Biological substances are an important driver – and have become one of the main trends in the pharmaceutical industry, spreading to more and more regions and people.
In cancer immunotherapy, the body’s own immune system is stimulated to fight against tumor cells, for instance with monoclonal antibodies. Antibody-drug conjugates (ADCs) ensure that cytostatics exclusively reach the cancer cells as loads of the antibodies to unfold their effect, thus sparing “healthy” cells and preventing side effects. Kinase inhibitors, in turn, repair defect signaling cascades and are able to slow down unrestrained cell growth, for example in chronic myeloid leukemia.
Treatment for the masses
Biosimilars – replica products of biopharmaceuticals whose patent has expired – also have increasingly entered the market, for instance for the treatment of rheumatoid arthritis. Authorities such as the U.S. Food and Drug Administration (FDA) promote their approval to make such drugs available faster at lower prices for more people to foster therapeutic advances while reducing costs at the same time.
Intensive research and development, as well as the adaption of production environments to the demands of highly potent or highly sensitive substances and stricter legal requirements are also changing the cooperation between drug producers and equipment manufacturers – from a mere business relationship to a partner-like collaboration. This is why we at Bosch Packaging Technology are at your disposal with a solution that matches your requirements – from a tailor-made single machine through to complete solutions, where we accompany your entire process before, during and after the project with profound market knowledge and technological expertise.
Are you interested to learn more about our comprehensive portfolio? Please feel free to contact us or visit us at Interpack: hall 6, booth A30-C58.
- Learn more about our solutions for the pharmaceutical industry
Dr. Johannes Rauschnabel
Chief Pharma Expert